Tepotinib

Drug Profile

Tepotinib

Alternative Names: EMD-1214063; MSC-2156119; MSC-2156119J

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator EMD Serono; Merck KGaA; Merck Serono
  • Class Antineoplastics; Nitriles; Piperidines; Pyridazines; Pyrimidines; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adenocarcinoma; Hepatocellular carcinoma; Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 07 Oct 2016 Efficacy and adverse events data from a phase Ib/II trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 04 Jul 2016 Phase-II clinical trials in Adenocarcinoma (Late-stage disease, Second-line therapy or greater, Treatment-experienced) in France and Belgium (PO) (EudraCT2015-005696-24)
  • 13 Jun 2016 Phase-II clinical trials in Adenocarcinoma (Late-stage disease, Second-line therapy or greater, Treatment-experienced) in Spain (PO) (EudraCT2015-005696-24)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top